Bristol-Myers Squibb Company (BMY)
| Market Cap | 120.14B |
| Revenue (ttm) | 48.30B |
| Net Income (ttm) | -8.95B |
| Shares Out | 2.03B |
| EPS (ttm) | -4.41 |
| PE Ratio | n/a |
| Forward PE | 8.78 |
| Dividend | $2.48 (4.19%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 8,754,017 |
| Open | 61.23 |
| Previous Close | 61.05 |
| Day's Range | 59.18 - 61.49 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.44 |
| Analysts | Hold |
| Price Target | 58.00 (-2.03%) |
| Earnings Date | Apr 24, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $58.0, which is a decrease of -2.03% from the latest price.
News
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to value/ defensive stocks. This is significantly aided by the double beat FQ4'...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb occupy leading positions in the cancer therapy market. Each of them has advantages, as well as dark spots in the portfolio of medications relative to the comparator. In ...
10 Undervalued Dividend Growth Stocks: March 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, an...
Bristol-Myers Squibb: Why I'm Still Bullish
I reiterate my "Buy" rating on Bristol-Myers Squibb due to its undervaluation, strong growth portfolio, and significant cost-saving initiatives. BMY's drug portfolio expansion and strategic productivi...
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--BMS Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma.
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025.
Bristol-Myers Squibb Company (BMY) Presents at Leerink Partners 2025 Global Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ET Company Participants Roland Chen - Head of Development for Immunology, Cardi...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
NEW YORK , March 11, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by 2seventy bio, Inc. (NASDAQ: TSVT) and its board of directors concerning the proposed a...
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
On Monday, Bristol Myers Squibb & Co BMY agreed to acquire 2seventy bio, Inc. TSVT at $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million...
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday.
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstan...
Final Trade: VRSK, BMY, VZ, APO, GM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
On Saturday, Bristol Myers Squibb & Co BMY revealed data from the pivotal Phase 3 POETYK PsA-2 trial (IM011-055) evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active p...
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AAD--Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared.
I'm Locking 9-11% FCF Yields On These Dividend Icons
Bristol Myers Squibb and Alexandria Real Estate offer strong free cash flow yields and appealing dividends, making them attractive in volatile markets. BMY's low valuation, robust drug pipeline, and c...
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Unresectable...
Final Trade: SBUX, GAP, SLV, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Bristol-Myers Squibb Company (BMY) Presents at 45th Annual TD Cowen Health Care Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ET Company Participants Adam Lenkowsky - Executive Vice President & Chief Commercial Officer ...
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / E...
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.
Bristol Myers Colorectal Cancer Treatment Goes Under Priority FDA Review
On Monday, the FDA accepted the supplemental biologics license application (sBLA) for Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment op...
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates ...